嵌合抗原受体自然杀伤细胞（CAR-NK）疗法：2024年美国血液学会年会的最新进展
CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting.
作者信息
Kong Ran, Liu Bingyu, Wang Hua, Lu Tiange, Zhou Xiangxiang
机构信息
Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China.
Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.
出版信息
J Hematol Oncol. 2025 Mar 1;18(1):22. doi: 10.1186/s13045-025-01677-3.
Natural killer cells, integral to the innate immune response, exhibit the inherent capacity to identify and eliminate cancer cells without prior exposure, positioning them as prime candidates for immunotherapeutic strategies. Chimeric antigen receptor-engineered natural killer (CAR-NK) cells obviate the requirement for human leukocyte antigen compatibility, simplifying personalized schedules and facilitating the manufacture of off-the-shelf products. In addition, CAR-NK cell therapy possesses lower risk of cytokine release syndrome and neurotoxicity, benefitting patients with higher security. Nevertheless, CAR-NK cell therapy is also confronted with challenges, including but not limited to short lifespan and restrictions from tumor microenvironment. Here, we summarized the latest advancements in the preclinical investigations and clinical trials of CAR-NK cell therapy from the 2024 ASH Annual Meeting.
自然杀伤细胞是先天免疫反应的重要组成部分，具有在无需预先接触的情况下识别和消除癌细胞的内在能力，使其成为免疫治疗策略的主要候选对象。嵌合抗原受体工程化自然杀伤（CAR-NK）细胞消除了对人类白细胞抗原相容性的要求，简化了个性化治疗方案，并便于现货产品的生产。此外，CAR-NK细胞疗法具有较低的细胞因子释放综合征和神经毒性风险，为患者提供了更高的安全性。然而，CAR-NK细胞疗法也面临挑战，包括但不限于寿命短和肿瘤微环境的限制。在此，我们总结了2024年ASH年会CAR-NK细胞疗法临床前研究和临床试验的最新进展。
Zotero 插件